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Objective: To prevent hemoptysis and relapse during subsequent chemo-
therapy-induced neutropenia in patients with localized forms of invasive
pulmonary aspergillosis, we adopted an aggressive surgical approach.
Methods: From 1988 to 1996, 18 patients with hematologic diseases were
referred with the diagnosis of localized invasive pulmonary aspergillosis.
The diagnosis was based on clinical features, failure to respond to
antibiotic therapy, an air crescent sign suggestive of aspergillosis on the
computed tomographic scan (39%), and retrieval of fungi by bronchoalveo-
lar lavage (44%). Results: The following procedures were done: one pneu-
monectomy, four bilobectomies, seven lobectomies, six wedge resections,
and one lobectomy with wedge resection (one patient had two procedures).
No perioperative deaths or complications occurred. The histologic exami-
nation confirmed the diagnosis of invasive pulmonary aspergillosis in 12
patients. The six other diagnoses were as follows: one case of classic
aspergilloma, one case of pneumonia, and four cases of pulmonary abscess.
According to univariate analysis, thoracic pain was less common in the
group with noninvasive pulmonary aspergillosis (1/6) than in the group
with invasive pulmonary aspergillosis (8/12) (p < 0.05). Sixteen patients
required subsequent hematologic treatments. Sixty-six percent of the
patients are alive with a mean follow-up of 29.1 6 27.8 months (range 2 to
103 months), with no statistically significant difference between the invasive
and the noninvasive pulmonary aspergillosis groups. Five patients died of
a recurrence of their malignant disease at a mean of 17.2 6 12.5 months
(range 2 to 30 months), and one had a cerebral recurrence of Aspergillus
infection during a bone marrow transplantation 3 months later. Conclusion:
Aggressive surgical management radically improves the prognosis of
invasive pulmonary aspergillosis, even if the surgical indications include
some nonmycotic infections because of the difficulty in establishing the
clinical diagnosis. (J Thorac Cardiovasc Surg 1998;115:63-9)
Patients with hematologic malignant diseases ne-cessitating high-dose chemotherapy or even
bone marrow transplantation are at risk for numer-
ous infectious complications.1, 2 The respiratory sys-
tem is particularly susceptible to such infections.
Among the most devastating infections are the
pulmonary mycoses.3 Fungal infections in patients
with acute leukemia who undergo induction chemo-
therapy are caused in 58% of cases by Candida and
in 30% by Aspergillus.4, 5
The prognosis of invasive pulmonary aspergillosis
(IPA) is poor.6 However, in selected patients with a
localized lesion suspected to be a form of IPA, the
optimal mode of treatment remains undefined. The
current study reports our experience in the surgical
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management of 18 patients with pulmonary lesions
highly suspected to be IPA. Our approach prevented
hemoptysis and allowed subsequent cytotoxic treat-
ment with prolonged neutropenia.
Patients and methods
From 1988 to 1996, in the Department of Hematology
in Nantes University Hospital, among 1600 patients who
received intensive cytotoxic chemotherapy, 80 cases of
IPA were diagnosed (5%). Surgical resection was consid-
ered for patients with a good hematologic response to
therapy (e.g., normal peripheral counts after drug-induced
aplasia: polymorphonuclear cells . 1500/ml), normal pul-
monary function with a good pulmonary reserve, and
strong probability of localized IPA.
Eighteen consecutive patients of the 80 (22.5%) who
met these criteria underwent surgical resection. The pa-
tients comprised 10 women and eight men (median 47
years, range 15 to 74 years) who were treated with
high-dose chemotherapy for acute myelogenous leukemia
(n 5 13), acute lymphoblastic leukemia (n 5 3), and
multiple myeloma (n 5 2). The diagnosis of IPA was
suspected during aplasia after the first induction of che-
motherapy for all patients, except for two who were
treated by salvage chemotherapy for relapse. No patient
was known to have active fungal or bacterial infection at
the time chemotherapy was performed. The median du-
ration of chemotherapy-induced neutropenia (polymor-
phonuclear cells , 500/ml) was 33 days (range 16 to 60
days).
The diagnosis (Table I) of IPA was based on clinical
features (fever 16/18, chest pain 9/18, hemoptysis 5/18),
failure to respond to broad-spectrum antibiotic therapy,
the presence of an air crescent sign on the computed
tomographic (CT) scan (7/18), and retrieval of fungi by
bronchoalveolar lavage (BAL) (8/18). The diagnosis was
considered to be almost certain when the BAL results
showed abnormalities, and in the 10 other patients the
association of the clinical and radiologic signs rendered
the diagnosis highly likely. Serologic examination was not
routinely used in our series because negativity is common
during aplasia. The most common site of these lesions was
the upper lobe of the lung (15/18). Five lesions were
located in the lower lobe and three in the middle lobe.
Five patients had multiple locations, and one had bilateral
lesions.
Once the diagnosis of IPA was suspected, 17 patients
received an antifungal medical treatment for 32 days
(range 12 to 90 days) before surgical treatment. Ampho-
tericin B (1 mg/kg per day) alone was given in eight
patients, and in nine other patients it was followed by oral
itraconazole (400 mg per day). Itraconazole was never
given alone.
The average preoperative polymorphonuclear cell
count was 6721/ml (600 to 17,000/ml) and the average
preoperative platelet count was 245,000/ml (range 30,000
to 745,000/ml). Only two patients received platelet trans-
fusions before the operation. Results of coagulation stud-
ies were within normal limits in all patients. In two
patients the operation was performed on an urgent basis
because the mass was located close to the main pulmonary
artery.
Operative procedures included one pneumonectomy,
four bilobectomies, seven lobectomies, six wedge resec-
tions, and one lobectomy with wedge resection (one
patient had two procedures). Usually the pleural surface
was not adherent to the chest wall, but sometimes smooth
pleural adhesions were present and were easily dissected.
No perioperative or postoperative deaths or complica-
Table I. Summary of the patients’ symptoms
Patient No. Age (yr)
Hematologic
disease Symptoms* BAL Histology
1 52 Myeloma Hemoptysis, chest pain 2 IPA
2 15 LAL Fever, chest pain, hemoptysis 1 IPA
3 53 MAL Fever, chest pain, AC sign 1 IPA
4 47 MAL Fever, hemoptysis, AC sign 2 IPA
5 48 Myeloma Fever, AC sign 1 IPA
6 74 MAL Fever 2 IPA
7 54 MAL Fever, chest pain 1 IPA
8 40 MAL Fever, AC sign 1 IPA
9 29 MAL Fever, chest pain, AC sign 1 IPA
10 30 MAL Fever, chest pain, AC sign 2 IPA
11 51 MAL Fever, chest pain 2 IPA
12 29 MAL Fever, chest pain 1 IPA
13 38 MAL Fever 2 Abscess
14 29 MAL Fever, chest pain, AC sign 2 Abscess
15 57 MAL Hemoptysis 2 Abscess
16 26 LAL Fever 2 Abscess
17 52 MAL Fever 1 ASP
18 31 LAL Fever 2 Pneumonia
BAL, Bronchoalveolar lavage; LAL, lymphoblastic acute leukemia; MAL, myeloblastic acute leukemia; AC, air crescent; IPA, invasive pulmonary
aspergillosis; ASP, aspergilloma.
*All patients had pneumonia and neutropenia.
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tions occurred, in particular, no bleeding, no empyema,
and no residual space problems.
The histologic examination of the resected specimens
confirmed the diagnosis of IPA in 12 patients in whom
invasion of blood vessels by the fungus led to ball or
triangular pulmonary infarction (Fig. 1). This infarcted
piece of tissue was often separated from the surrounding
tissues by phagocytes. In the six other patients, the
diagnoses were as follows: classic aspergilloma, one case;
pneumonia, one case; and pulmonary abscess, four cases,
although three of them had Aspergillus colonization with-
out the typical invasion of blood vessels by Aspergillus that
defines IPA.
According to univariate analysis, in the group with
noninvasive pulmonary aspergillosis (NIPA) fewer pa-
tients had thoracic pain (1/6) than in the group with IPA
(8/12) (p , 0.05); the likelihood of finding an air crescent
sign on the CT scan was less (1/6 in the NIPA group vs
6/12 in the IPA group), as was the likelihood of retrieving
aspergillus by BAL (1/6 in the NIPA group vs 7/12 in the
IPA group).
Sixteen patients received antifungal therapy after the
operation. Sixteen patients required subsequent hemato-
logic treatments: six received antileukemic chemotherapy
and 10 received high-dose chemotherapy and total-body
irradiation followed by autologous stem cell transplanta-
tion. All received prophylactic amphotericin B during
additional neutropenia. At a mean follow-up of 29.1 6
27.8 months (range 2 to 103 months), 66.7% of the
patients are alive (range 2 to 103 months). There is no
statistically significant difference between the IPA and the
NIPA groups. Five patients died (27.8%) of a recurrence
of their malignant disease at a mean of 17.2 6 12.5
months (range 2 to 30 months), and one died (5.5%) of a
suspected cerebral recurrence of Aspergillus infection dur-
ing a bone marrow transplantation 3 months later (autop-
sy not done).
Discussion
Aspergillus is a ubiquitous fungus present in the
air, and its inhalation is extremely common. The
most frequent manifestation of pulmonary aspergil-
losis is the saprophytic form, when fungus colonizes
and proliferates in a preexisting cavity.7 However, in
immunocompromised patients aspergillosis behaves
like an opportunistic infection, giving rise to IPA.8
As already reported by others, in our group of
immunocompromised patients the risk of IPA was
5%.9, 10 The presence of construction activity con-
tiguous to a department of hematology is a widely
recognized risk factor for IPA,11 and the risk of
Fig. 1. Typical IPA. Upper left, Macroscopic view of the ball infarction. Lower left, Bronchopulmonary
invasion by Aspergillus (Grocott coloration). Lower right, Bronchopulmonary necrosis. Upper right, Blood
vessel invasion (arrow) with ensuing thrombosis and infarction surrounded by an acute inflammation.
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development of IPA also increases progressively
with the number of granulocytopenic days, reaching
a plateau of 70% among patients with granulocyto-
penia for more than 34 days.12 In our group of
patients, the mean duration of granulocytopenia was
33 days.
The prognosis of IPA in patients with leukemia
remains poor. The mortality rate reaches an average
of 50% to 60% when IPA occurs during chemother-
apy-induced neutropenia and can exceed 90% in the
setting of bone marrow transplantation.6 The pre-
requisites for improving prognosis include early
recognition of IPA, shortening the neutropenic pe-
riod with the use of hematopoietic growth factors,
effective antifungal treatment,13 and surgical resec-
tion of localized IPA.14-17
The definitive diagnosis of IPA must be made by
histologic studies. Bronchopulmonary necrosis, pa-
renchymal and blood vessel invasion by fungal hy-
phae with ensuing thrombosis, infarction, and acute
inflammation define IPA. Cavities occur by separa-
tion of the infarcted lung from adjacent viable lung,
resulting in an intracavitary sequestrum of necrotic
lung tissue.18 The roentgenologic correlation of this
sequence of events is the air crescent sign.19 Unlike
classic aspergilloma, in which the cavity preexists the
fungal invasion, in IPA the proposed pathogenesis
of cavity formation invokes destruction of lung
parenchyma by phagocyte-derived proteolytic en-
zymes at the periphery of the infarct.20
Severe thrombocytopenia in patients with acute
leukemia who undergo chemotherapy usually pre-
vents biopsy of any tissue. Thus establishing a defin-
itive diagnosis (i.e., histologic) in the absence of
highly sensitive serologic tests is usually not possible
before the surgical resection. Careful work from the
early 1980s showed that a positive BAL culture
during neutropenia (,500/ml) has a 90% positive
predictive value for IPA.21, 22 Of the eight BAL
cultures considered to be positive, one (12.5%) has
been retrospectively classified in the NIPA group,
and this margin of error does not differ from those
in previous studies. In that case, the pathologist
diagnosed an intrabronchial aspergilloma. The real
problem is not the false positivity, however, but
rather the false negativity of BAL. Of the 10 patients
with negative BAL cultures, five had histologically
proved IPA.
IPA is common enough to be considered early in
the course of neutropenic patients. The presence of
neutropenia, pneumonia, persistent fever despite
broad-spectrum antibiotic therapy, hemoptysis, and
an air crescent sign on the CT scan are the main
criteria to suggest IPA in immunocompromised
patients. Because of the severity of the prognosis,
when the BAL culture remained negative, we con-
sidered the diagnosis of IPA to be highly likely when
at least three of those five criteria were present. Of
the 10 patients with negative BAL cultures, five had
histologically proved IPA and five did not. In this
group of 10 patients, seven met three criteria, one
met four criteria, and two met all five criteria. When
all five criteria were present the diagnosis of IPA
was never incorrect. Among the total group of 18
patients, chest pain was the single discriminative
sign between the IPA and the NIPA groups (16.6%
in the NIPA group vs 66.6% in the IPA group) (p ,
0.05), and that could be explained by the pleural
inflammation that is present in the IPA group.
Nevertheless, the prognosis of IPA relapse is so
poor that when clinical criteria suggestive of IPA are
present, it is difficult to exclude surgery merely
because the patient has no chest pain. CT scan could
help to improve the diagnosis. Like others, we
believe the air crescent sign is an insensitive marker
for lung cavitation in IPA,18 appearing long after the
onset of the disease. However, another CT sign, the
halo sign, appears earlier during the evolution of
IPA.23 In a recent report, at least one halo sign was
present in more than 90% of patients with IPA, and
the sign was very indicative of IPA in neutropenic
patients.24 This CT sign must be given more atten-
tion in the future.
At present, clinicians have two agents that are
therapeutically useful for invasive aspergillosis: am-
photericin B and itraconazole.6 However, antifungal
treatment must be given for long periods, for exam-
ple, 6 months after hematologic recovery.24 Despite
a well-conducted treatment, two severe complica-
tions have been observed. First, severe hemoptysis is
common after apparently successful antifungal
treatment.25 Second, for patients with hematologic
malignant diseases, additional cytotoxic chemother-
apy is often necessary to achieve or maintain the
response or remission of the underlying disease
before the antifungal treatment has been com-
pleted. The rate of IPA relapse during subsequent
neutropenia is high, even after large doses of am-
photericin B, because persistent intracavitary fungal
growth may serve as a reservoir for recurrent fungal
invasion in patients with prolonged neutropenia or a
repeated episode of severe neutropenia.26 In two
patients, surgery was performed on an urgent basis
because the mass was located close to the main
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pulmonary artery and the risk of massive hemoptysis
was high. Early surgical resection seems effective in
preventing life-threatening hemoptysis.15, 16, 24, 27
The risk of hemoptysis is higher after recovery of
granulocytes,25 but fatal bleeding can occur more
than 6 weeks after the beginning of amphotericin B
therapy or hematologic recovery.28 Surgery also
seems effective in preventing IPA recurrence, with
one documented case of IPA relapse among 54
(1.8%) other cases already reported in the litera-
ture.15-17, 24 In our data, one patient died of what we
suspected to be invasive cerebral aspergillosis during
a bone marrow transplantation 3 months after the
surgical resection of a localized IPA. Other modal-
ities (intravenous amphotericin B or oral itracon-
azole) for prevention of IPA reactivation can be
discussed.29, 30 However, the mandatory rapid rein-
stitution of cytotoxic treatment for the underlying
hematologic disease implies a new period of neutro-
penia before the antifungal treatment is completed,
and few patients with persistent neutropenia and
invasive aspergillosis survive.6 Moreover, a small
number of patients with persistent neutropenia have
responded to liposomal amphotericin31 or itracon-
azole32 during neutropenia, but resolution of as-
pergillosis has followed neutrophil recovery. In pa-
tients with localized IPA and no contraindication to
surgery, the risks of the surgical resection are lim-
ited (no complications in our patients). Finally, the
benefit of surgery is rapid treatment of areas of
infection, which allows for rapid retreatment with
protocols including high-dose chemotherapy and
prevention of life-threatening hemoptysis.
As in other series,15, 16 the most common proce-
dure performed was a lobectomy without any com-
plications or deaths. This contrasts strongly with the
treatment program for patients with classic aspergil-
loma. However, young age of the patient, good
function and good reexpansion of the residual lung,
and noninduration of the hilar structure by tubercu-
losis are the rule in localized IPA.16 Moreover,
surgery was always performed after the end of
neutropenia, and only two patients required platelet
transfusion before surgery. That explains the ab-
sence of bleeding and infectious complications. Be-
cause the recovery must be rapid without any pro-
longed air leak to permit treatment of the
underlying hematologic disease, and also because
the disease is often more diffuse inside the lobe than
the CT scan indicates, we usually performed lobec-
tomies rather than wedge resections. We have not
used video-assisted surgery. Pleural adhesions, in-
flammation of the hilar structure, and location of
the lesion close to the branches of the pulmonary
artery or even the main pulmonary artery itself are
not favorable conditions for minimally invasive sur-
gery.
In conclusion, a poor outcome after hemoptysis
and IPA relapses is obvious.6 Surgery for these
indications appears safe (rapid recovery, no compli-
cations, no deaths). Therefore we advocate that
surgical therapy must be performed as soon as the
diagnosis of localized IPA is suggested by clinical
and radiologic criteria, even if not confirmed by
histologic studies.
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Discussion
Dr. Marvin Pomerantz (Denver, Colo.). These authors
operated on 18 patients with presumed IPA without a
death or a complication. This is certainly a monumental
task. As they pointed out, only 12 of these 18 patients did
have IPA, but one had an aspergilloma and the other four
had other pulmonary infections. However, I believe the
title of their paper gives the impression that they are
operating on patients during a neutropenic phase, when,
actually, at the time of the operation, the polymorphonu-
clear cell count was over 6000/ml and the platelet count
was almost 250,000/ml. They also had the luxury of having
their patients receive antibiotic therapy for an average of
32 days.
I have only one question for the authors. They reported
having 80 patients with presumed pulmonary aspergillosis,
and they operated on 18. What happened to the other 62
patients?
Dr. Lary A. Robinson (Tampa, Fla.). Three years ago
we presented our series of 16 immunocompromised pa-
tients with IPA who underwent major pulmonary resec-
tions. Most of them had undergone bone marrow trans-
plantation. We agree that aggressive surgical management
of this problem offers their only chance of survival after
bone marrow transplantation. In the literature, the mor-
tality from IPA in this group after medical treatment is
95% and up.
I would like to make several comments. The diagnosis is
often hard to make before the operation. Bronchoscopic
examinations and needle biopsies are not necessary and
did not help us to make the diagnosis.
One important radiographic sign is the halo sign. Most
IPAs will have a halo on chest CT scan if they are
discovered early in the course of the infection and if the
patient is neutropenic. When the white cell counts re-
cover, however, the white cells apparently are able to
phagocytize the necrotic material in the center of the
Aspergillus mass. Then they end up having a circle of dense
material around the cavitary abscess, which radiographi-
cally on CT scan is the air crescent sign. These two signs
were quite diagnostic for IPA, at least in our hands.
Incidentally, most of our patients were operated on when
they had very few white cells, usually fewer than 500 white
cells, and the halo sign was very common.
Initially in our experience we waited for a while before
operating, but the patients then became quite sick. This
delay in operation led to surgery on very sick patients and
some subsequent deaths. We have changed to early oper-
ation on these patients, most of the time while they are
neutropenic. We did not have any pleural space problems,
pleural infections, or problems with bleeding in these
neutropenic patients. Our best results were with early
operation.
The deaths that we had were in allogeneic patients
undergoing bone marrow transplantation. We had five
such patients, and three of them died of diffuse alveolar
hemorrhage 7 to 10 days after the operation. The one
patient who required a ventilator before the operation
also died after the operation.
I would like to ask the authors one question: Have you
had any experience with IPA in patients who have had
bone marrow transplantation, and were any of those
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allogeneic transplant patients? That group had the highest
mortality in our hands. Otherwise, the other patients did
extremely well.
Dr. Jhingook Kim (Seoul, Korea). Because the compli-
cated aspergillosis region is not affected by the malignant
disease, it is not necessary to resect a margin of tissue. I try
to save as much of the normal lung as possible. Therefore,
I prefer a retroresection or a precise excision of the lesion
after adequate and sufficient use of amphotericin.
If the lesion is in the middle of the upper lobe, do you
still prefer to do a right upper lobectomy rather than just
a precise excision of the region of the aspergillosis?
Dr. Khaled M. Al-Kattan (Riyadh, Saudi Arabia). I have
two questions. First, some of these lesions are multiple,
and even if they have caused hemoptysis, it can be difficult
to tell which one is responsible, especially after bone
marrow transplantation. What do you do with these?
Second, some of those lesions are small, and the
oncologist or the infectious disease group has fairly good
success eliminating them with high doses of amphotericin.
How do you know when to operate? How do you decide
that the medical treatment is a failure or should not be
tried?
Dr. Baron. Thank you for your comments. Dr. Pomer-
antz, the 62 patients with IPA who were not treated
surgically had more diffuse disease, with bilateral lesions,
which contraindicated surgical resection.
We use the term neutropenia because the disease always
developed in patients during a neutropenic period caused
by chemotherapy for hematologic disease. However, ex-
cept when the risk of hemoptysis was too high, and that
occurred two times in our series, we did not operate on
those patients before the end of neutropenia.
To respond to your comment about the use of early
antifungal treatment and the use of hematopoietic growth
factors, the mass does not grow fast enough to force us to
operate before the end of neutropenia. Usually our main
surgical indication was to prevent an IPA relapse during
the subsequent period of neutropenia mandatory to treat
the underlying disease. We are aware from other reports
that localized forms of IPA have been resected success-
fully during the neutropenic period, but so far that is not
our policy.
Dr. Robinson, you emphasized the halo sign. In the
future we will have to pay more attention to this CT sign
because it appears earlier during the evolution of the
disease than does the air crescent sign. We have not
operated on those kinds of patients during or after a bone
marrow transplantation. All 18 patients were operated on
after the initial program of chemotherapy for hematologic
disease.
Dr. Kim inquired about the advisibility of using wedge
resection or lobectomy. We think that the disease is often
more diffuse in the lobe than we can tell on the CT scans,
so we advocate wide resection. However, when the nodule
is a very peripheral nodule, we have done wedge resection.
Dr. Kim. Let me clarify my question. When the region
is deep inside the lung parenchyma, too deep for wedge
resection, do you prefer lobectomy or do you just open the
lung and take out the dead region precisely?
Dr. Baron. Usually we have done a lobectomy.
Dr. Deslauriers. The other question concerned the
timing of operation versus continuing medical treatment.
When do you decide that?
Dr. Baron. The problem with those patients is the
context, that context being their hematologic disease. We
cannot wait 3 months to treat the IPA, and we need at
least 3 months of effective antifungal treatment to cure the
IPA. We operate as soon as the neutropenia period is
completed, but we never have operated before the com-
pletion of the neutropenia, because we wanted to avoid
any complication of the neutropenic period.
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